CYP2A6 genotype and the metabolism and disposition kinetics of nicotine
- PMID: 17112802
- DOI: 10.1016/j.clpt.2006.08.011
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine
Abstract
Background and objective: The liver enzyme cytochrome P450 (CYP) 2A6 is primarily responsible for the metabolism of nicotine. Variants in the CYP2A6 gene have been associated with altered nicotine metabolism and with effects on smoking behavior. Our objective was to determine the relationship between variant CYP2A6 genotypes and the disposition and metabolism of nicotine administered intravenously.
Methods: Intravenous infusions of deuterium-labeled nicotine and cotinine were administered to 278 healthy twin volunteers, most of whom were white. They were genotyped for CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*7, CYP2A6*8, CYP2A6*9, CYP2A6*10, and CYP2A6*12.
Results: On the basis of the fractional clearance of nicotine to cotinine and on the plasma ratio of 3'-hydroxycotinine to cotinine, both shown to be indicators of CYP2A6 enzymatic activity, subjects were classified into 3 groups. Group 1 included wild-type variant CYP2A6*1/*1 (n=215) and was assumed to have 100% activity. Group 2 included *1/*9 (n=21) and *1/*12 (n=12), which averaged about 80% of normal activity. Group 3 included *1/*2 (n=10), *1/*4 (n=2), *9/*12 (n=3), *9/*4 (n=2), and *9/*9 (n=3), which averaged about 50% of normal activity. The mean total plasma clearance of nicotine (+/-SD) was 18.8+/-6.0, 15.5+/-4.9, and 11.7+/-5.1 mL.min-1.kg-1 in groups 1, 2, and 3, respectively, and group 1 had significantly faster clearance than group 2 (P<.05) and group 3 (P<.01). Overall, groups 2 and 3 also had lower total clearance of cotinine, had longer half-lives for nicotine and cotinine, and excreted in the urine a greater fraction of the nicotine dose as unchanged nicotine and nicotine glucuronide and excreted less as 3'-hydroxycotinine compared with group 1.
Conclusions: We provide novel pharmacokinetic and metabolic data on nicotine after systemic dosing in relation to common CYP2A6 genotypes. Our data will enhance the interpretation of CYP2A6 genotypic data as used in association studies of smoking behavior and its health consequences.
Similar articles
-
Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance.Clin Pharmacol Ther. 2006 Nov;80(5):522-30. doi: 10.1016/j.clpt.2006.08.006. Clin Pharmacol Ther. 2006. PMID: 17112808 Clinical Trial.
-
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.Clin Pharmacol Ther. 2008 Jan;83(1):115-21. doi: 10.1038/sj.clpt.6100246. Epub 2007 May 23. Clin Pharmacol Ther. 2008. PMID: 17522595 Free PMC article. Clinical Trial.
-
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.Clin Pharmacol Ther. 2004 Jul;76(1):64-72. doi: 10.1016/j.clpt.2004.02.011. Clin Pharmacol Ther. 2004. PMID: 15229465
-
Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.Drug Metab Pharmacokinet. 2005 Aug;20(4):227-35. doi: 10.2133/dmpk.20.227. Drug Metab Pharmacokinet. 2005. PMID: 16141602 Review.
-
Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.Pharmacogenomics. 2007 Oct;8(10):1385-402. doi: 10.2217/14622416.8.10.1385. Pharmacogenomics. 2007. PMID: 17979512 Review.
Cited by
-
CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers.Pharmacogenet Genomics. 2013 Apr;23(4):232-5. doi: 10.1097/FPC.0b013e32835f834d. Pharmacogenet Genomics. 2013. PMID: 23462429 Free PMC article.
-
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.Pharmacogenet Genomics. 2012 Sep;22(9):695-708. doi: 10.1097/FPC.0b013e3283540217. Pharmacogenet Genomics. 2012. PMID: 22547082 Free PMC article. Review. No abstract available.
-
Pharmacogenetic Variation in Neanderthals and Denisovans and Implications for Human Health and Response to Medications.Genome Biol Evol. 2023 Dec 1;15(12):evad222. doi: 10.1093/gbe/evad222. Genome Biol Evol. 2023. PMID: 38051947 Free PMC article.
-
CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.Br J Cancer. 2011 Mar 29;104(7):1126-34. doi: 10.1038/bjc.2011.24. Epub 2011 Mar 1. Br J Cancer. 2011. PMID: 21364592 Free PMC article.
-
Finding genomic function for genetic associations in nicotine addiction research: the ENCODE project's role in future pharmacogenomic analysis.Pharmacol Biochem Behav. 2014 Aug;123:34-44. doi: 10.1016/j.pbb.2014.01.009. Epub 2014 Jan 31. Pharmacol Biochem Behav. 2014. PMID: 24486638 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous